Several studies documented that first-generation EGFR TKIs improve the interaction between natural killer (NK) and tumor cells favoring immune-mediated cytotoxicity, indicating that EGFR inhibitors can enhance innate tumor immune surveillance (44–46). This evidence concerns the gene EGFR and neoplasm.